论文部分内容阅读
目的探讨脂肪肝对于聚乙二醇干扰素α和阿德福韦酯联合治疗慢性乙肝的疗效影响。方法选择2013年4月—2016年3月本院收治的慢性乙肝患者46例患者进行研究,均予以聚乙二醇干扰素α联合阿德福韦酯治疗,并分为对照组(未合并脂肪肝)20例和观察组(合并脂肪肝)26例,对比2组疗效。结果 2组的HBe Ag转换、病毒学应答、生化学应答率对比差异无统计学意义(P均>0.05)。结论脂肪肝不会影响到聚乙二醇干扰素α联合阿德福韦酯治疗慢性乙肝的疗效。
Objective To investigate the effect of fatty liver on the therapeutic effect of pegylated interferon alfa and adefovir dipivoxil on chronic hepatitis B patients. Methods 46 patients with chronic hepatitis B admitted to our hospital from April 2013 to March 2016 were enrolled in the study. All patients were treated with peginterferon alfa and adefovir dipivoxil, and were divided into control group (without combined fat Liver) 20 cases and observation group (with fatty liver) 26 cases, compared with two groups. Results There was no significant difference in HBe Ag conversion, virological response and biochemical response rate between the two groups (all P> 0.05). Conclusion Fatty liver does not affect the efficacy of peginterferon alfa and adefovir dipivoxil in the treatment of chronic hepatitis B.